Special Issue

Immune Responses to Papillomavirus Infections

Message from the Guest Editors

Human papillomavirus (HPV) infection is the most common sexually transmitted disease that causes approximately 5% of human cancers. Current prophylactic vaccines are effective at preventing HPV infections but provided no therapeutic effect on pre-existing HPV infections. Intriguingly, most HPV (about 90%) infections are cleared by hosts within 1-2 years after exposure. Understanding host control of HPV infections will potentially shed light on the development of novel therapy for HPV associated diseases and cancers. Innate and adaptive immunity have contributed to recognize and fight HPV infections. However, HPV has several mechanisms for circumventing the immune responses. The current issue covers research relating to how the immune system effectively clear papillomavirus infections, and what immune responses are key factors in this optimum outcome. We would like to invite you to share your recent findings or perspectives on host immunity to papillomavirus, including but not limited to innate and adaptive immune responses in preclinical models and human studies.

Guest Editors

Dr. Jiafen Hu

Department of Pathology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA

Dr. Vivien Béziat

Imagine Institute, University of Paris, Paris, France

Deadline for manuscript submissions

closed (30 June 2024)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/138626

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).